|Day Low/High||145.84 / 149.61|
|52 Wk Low/High||125.84 / 197.00|
AGN, AVA, ALK, RLI and CRT all recently were downgraded by TheStreet's Quant Ratings.
Clearly, the first half of the month shaped up better than the second half.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ALEX, CATS, EXTR, LAD Downgrades: AGN Initiations: LBC, MRBK, SBT Read on to get TheStreet Quant Ratings' detailed report:
Kate Warne, investment strategist at Edward Jones, talked to TheStreet about what Boeing's report means for U.S. companies with exposure to China, Apple's beat and how the healthcare sector is looking.
NEW YORK, Jan. 29, 2019 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Allergan plc.
Botox maker reports a fourth-quarter loss of $4.3 billion, a reversal from a year-earlier profit of $3.05 billion.
What we have seen of late from a number of chip producers really might be interpreted as pre-recessionary.
- Full-Year 2018 GAAP Net Revenues of $15.8 Billion; Q4 2018 GAAP Net Revenues of $4.1 Billion -
Campaign targets new generation of users with an updated, modern approach
Eight important companies report earnings between Monday and Tuesday. Don't miss them.
Allergan could move higher but some sort of retest of the December low seems in order in the short to intermediate term.
Jim Cramer's plan for getting through the heart of earnings season next week.
NEW ORLEANS, Jan. 25, 2019 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until February 19, 2019 to file lead plaintiff applications in a securities class action lawsuit against Allergan plc.
- First Quarter 2019 Cash Dividend of $0.74 Per Ordinary Share to be Paid on March 15, 2019; Record Date of February 15, 2019 -
Study Evaluated Pharmacokinetics, Efficacy and Safety of ABP 798 Compared to Rituximab in Patients With Moderate-to-Severe Rheumatoid Arthritis
Is it a retest based on the damage the Fed has already done, the result of a breakdown in trade talks or a sign of a slowing global economy?
Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C.
Jim Cramer talks about how this market is taking its cues from the positives, and shrugging off the negatives.
So far 2019 is proving to be a year where things have a habit of working out right.
The company is set to report earnings on Jan. 29, so traders have a couple of weeks to watch the action.
This will be the craziest reporting season we've seen in ages, says Jim Cramer. He's got your game plan for next week.
A three-year decline in the shares of the maker of Botox will take more than a two-week bounce to reverse.
Plus: Jim Cramer interviews Apple CEO Tim Cook about innovation, investments and healthcare technology.
The RMPIA index was up for the year, while the S&P 500, DJIA, Russell 2000 and Nasdaq all finished 2018 in the red.
- These initial data show the potential for the vast majority of patients to remain treatment free for at least 1 year -
- The facility, located in Kendall Square, is expected to open in 1Q2019 -
NEW ORLEANS, Jan. 4, 2019 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C.
Preclinical research demonstrated rapastinel positively modulates the NMDA receptor
DUBLIN, Jan. 3, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced it intends to release fourth quarter and full year 2018 financial results on Tuesday, January 29, 2019, prior to the open of U.
DUBLIN, Dec. 24, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Chairman and CEO Brent Saunders will present at the 37 th Annual J.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.